The Supreme Court of India's controversial decision to deny a patent for Novartis' cancer drug Glivec has put the country's approach to intellectual property law in the spotlight. As the debate around this ruling continues, Merck (NYSE: MRK ) is the latest big pharma to face patent headwinds in India. Its top-selling diabetes drug Januvia is now facing generic competition from Glenmark Pharma, and Merck is suing for patent infringement.
Is this something that investors should worry about today, or is this potentially a long-term threat that they should keep a close eye on? Health care analyst Max Macaluso discusses this case in the following video.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.